FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890943887> ?p ?o ?g. }

• W2890943887 endingPage "288" @default.
• W2890943887 startingPage "280" @default.
• W2890943887 abstract "The aim of the present study was to assess if the uninterrupted and prolonged administration of nanoparticles containing diethylcarbamazine (NANO-DEC) would cause liver, kidney and heart toxicity and then analyze for the first time its action in model of liver fibrosis. Thus, NANO-DEC was administered in C57BL/6 mice daily for 48 days, and at the end the blood was collected for biochemical analyzes. In the long-term administration assay, the evaluation of serological parameters (CK-MB, creatinine, ALT, AST and urea) allowed the conclusion that NANO-DEC prolonged administration did not cause hepatic, renal and cardiac damage. For fibrosis assays, C57BL/6 mice were divided into six groups: 1) control (Cont); 2) carbon tetrachloride (CCl4); 3) CCl4 + DEC 25 mg/kg; 4) CCl4 + DEC 50 mg/kg; 5) CCl4 + NANO-DEC 5 mg/kg and 6) CCl4 + NANO-DEC 12.5 mg/kg. Carbon tetrachloride induced hepatic fibrosis observed through increased inflammatory (TNF-α, IL-1β, COX-2, NO and iNOS) and fibrotic markers (TGF-β and TIMP-1), changes in the hepatic morphology, high presence of collagen fibers and elevated serum levels of AST, ALT and ALP. Treatment with NANO-DEC exhibited a superior anti-inflammatory and anti-fibrotic effects compared to the DEC traditional formulation, restoring liver morphology, reducing the content of collagen fibers and serological parameters, besides decreasing the expression of inflammatory and fibrotic markers. The present formulation of nanoencapsulated DEC is a well tolerated anti-inflammatory and anti-fibrotic drug and therefore could be a potential therapeutic tool for the treatment of chronic liver disorders." @default.
• W2890943887 created "2018-09-27" @default.
• W2890943887 creator A5004291825 @default.
• W2890943887 creator A5021835234 @default.
• W2890943887 creator A5023791771 @default.
• W2890943887 creator A5028210623 @default.
• W2890943887 creator A5030003593 @default.
• W2890943887 creator A5038322332 @default.
• W2890943887 creator A5039415718 @default.
• W2890943887 creator A5045176516 @default.
• W2890943887 creator A5081957918 @default.
• W2890943887 date "2018-11-01" @default.
• W2890943887 modified "2023-10-18" @default.
• W2890943887 title "A new diethylcarbamazine formulation (NANO-DEC) as a therapeutic tool for hepatic fibrosis" @default.
• W2890943887 cites W1490817952 @default.
• W2890943887 cites W1566219902 @default.
• W2890943887 cites W1593295279 @default.
• W2890943887 cites W1971094896 @default.
• W2890943887 cites W1971207761 @default.
• W2890943887 cites W1975212413 @default.
• W2890943887 cites W1988564036 @default.
• W2890943887 cites W1996666440 @default.
• W2890943887 cites W1996829989 @default.
• W2890943887 cites W1997834526 @default.
• W2890943887 cites W2000723389 @default.
• W2890943887 cites W2005066650 @default.
• W2890943887 cites W2007672578 @default.
• W2890943887 cites W2008052068 @default.
• W2890943887 cites W2045295282 @default.
• W2890943887 cites W2055554232 @default.
• W2890943887 cites W2066232813 @default.
• W2890943887 cites W2066919199 @default.
• W2890943887 cites W2077119788 @default.
• W2890943887 cites W2082275473 @default.
• W2890943887 cites W2083068177 @default.
• W2890943887 cites W2087197000 @default.
• W2890943887 cites W2093807841 @default.
• W2890943887 cites W2101887269 @default.
• W2890943887 cites W2165156241 @default.
• W2890943887 cites W2168548243 @default.
• W2890943887 cites W2213478767 @default.
• W2890943887 cites W2263291696 @default.
• W2890943887 cites W2291913215 @default.
• W2890943887 cites W2307551625 @default.
• W2890943887 cites W2522922592 @default.
• W2890943887 cites W2562949639 @default.
• W2890943887 cites W2565367159 @default.
• W2890943887 cites W2602684234 @default.
• W2890943887 cites W2606062902 @default.
• W2890943887 cites W2735527928 @default.
• W2890943887 cites W2735790845 @default.
• W2890943887 cites W2740198797 @default.
• W2890943887 cites W2750200819 @default.
• W2890943887 cites W2803708828 @default.
• W2890943887 doi "https://doi.org/10.1016/j.intimp.2018.09.010" @default.
• W2890943887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30219503" @default.
• W2890943887 hasPublicationYear "2018" @default.
• W2890943887 type Work @default.
• W2890943887 sameAs 2890943887 @default.
• W2890943887 citedByCount "3" @default.
• W2890943887 countsByYear W28909438872022 @default.
• W2890943887 crossrefType "journal-article" @default.
• W2890943887 hasAuthorship W2890943887A5004291825 @default.
• W2890943887 hasAuthorship W2890943887A5021835234 @default.
• W2890943887 hasAuthorship W2890943887A5023791771 @default.
• W2890943887 hasAuthorship W2890943887A5028210623 @default.
• W2890943887 hasAuthorship W2890943887A5030003593 @default.
• W2890943887 hasAuthorship W2890943887A5038322332 @default.
• W2890943887 hasAuthorship W2890943887A5039415718 @default.
• W2890943887 hasAuthorship W2890943887A5045176516 @default.
• W2890943887 hasAuthorship W2890943887A5081957918 @default.
• W2890943887 hasConcept C102124568 @default.
• W2890943887 hasConcept C126322002 @default.
• W2890943887 hasConcept C165901193 @default.
• W2890943887 hasConcept C178790620 @default.
• W2890943887 hasConcept C185592680 @default.
• W2890943887 hasConcept C203014093 @default.
• W2890943887 hasConcept C2777359374 @default.
• W2890943887 hasConcept C2777411658 @default.
• W2890943887 hasConcept C2777629521 @default.
• W2890943887 hasConcept C2780306776 @default.
• W2890943887 hasConcept C2780559512 @default.
• W2890943887 hasConcept C2993667909 @default.
• W2890943887 hasConcept C71924100 @default.
• W2890943887 hasConcept C98274493 @default.
• W2890943887 hasConceptScore W2890943887C102124568 @default.
• W2890943887 hasConceptScore W2890943887C126322002 @default.
• W2890943887 hasConceptScore W2890943887C165901193 @default.
• W2890943887 hasConceptScore W2890943887C178790620 @default.
• W2890943887 hasConceptScore W2890943887C185592680 @default.
• W2890943887 hasConceptScore W2890943887C203014093 @default.
• W2890943887 hasConceptScore W2890943887C2777359374 @default.
• W2890943887 hasConceptScore W2890943887C2777411658 @default.
• W2890943887 hasConceptScore W2890943887C2777629521 @default.
• W2890943887 hasConceptScore W2890943887C2780306776 @default.
• W2890943887 hasConceptScore W2890943887C2780559512 @default.
• W2890943887 hasConceptScore W2890943887C2993667909 @default.
• W2890943887 hasConceptScore W2890943887C71924100 @default.

• next